Natera, Inc. - Common Stock (NQ:NTRA)

415.54 +5.19 (+1.26%)

Delayed Quote Updated: 10:34 AM EDT, Oct 5, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Natera, Inc. - Common Stock

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

23 24 Next >

Q1 Rundown: Regeneron (NASDAQ:REGN) Vs Other Immuno-Oncology Stocks

June 22, 2025

Earnings results often indicate what direction a company will take in the months ahead. With Q1 behind us, let’s have a look at Regeneron (NASDAQ:REGN) and its peers.

Via StockStory

Topics Artificial Intelligence

3 Reasons We Love Natera (NTRA)

June 20, 2025

Natera has followed the market’s trajectory closely, rising in tandem with the S&P 500 over the past six months. The stock has climbed by 5% to $170 per share while the index has gained 1.1%.

Via StockStory

Topics Government Stocks

Here's How Much You Would Have Made Owning Natera Stock In The Last 10 Years ↗

June 13, 2025

Via Benzinga

A Look Back at Immuno-Oncology Stocks’ Q1 Earnings: Exact Sciences (NASDAQ:EXAS) Vs The Rest Of The Pack

June 11, 2025

As the Q1 earnings season comes to a close, it’s time to take stock of this quarter’s best and worst performers in the immuno-oncology industry, including Exact Sciences (NASDAQ:EXAS) and its peers.

Via StockStory

Topics Artificial Intelligence

Earnings Scheduled For May 8, 2025 ↗

May 08, 2025

Via Benzinga

Preview: Natera's Earnings ↗

May 07, 2025

Via Benzinga

Peering Into Natera's Recent Short Interest ↗

May 02, 2025

Via Benzinga

NTRA Q1 Earnings Call: Growth in Oncology and Women's Health Drives Guidance Increase

June 10, 2025

Genetic testing company Natera (NASDAQ:NTRA). reported Q1 CY2025 results beating Wall Street’s revenue expectations, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue...

Via StockStory

9 Health Care Stocks Whale Activity In Today's Session ↗

June 04, 2025

Via Benzinga

Natera Announces Medicare Coverage for Signatera™ Genome

June 04, 2025

From Natera, Inc.

Via Business Wire

SignateraTM Genome Clinical Performance Highlighted at ASCO 2025

June 02, 2025

From Natera, Inc.

Via Business Wire

2 Cash-Heavy Stocks for Long-Term Investors and 1 to Be Wary Of

June 02, 2025

Companies with more cash than debt can be financially resilient, but that doesn’t mean they’re all strong investments. Some lack leverage because they struggle to grow or generate consistent profits,...

Via StockStory

3 Mid-Cap Stocks Worth Your Attention

May 27, 2025

Large trillion-dollar companies are tightening their grip on the market, often by acquiring smaller rivals. This trend will likely pick up with new regulatory leadership, but a few mid-sized businesses...

Via StockStory

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

May 26, 2025

Via Benzinga

Natera to Present over 25 Signatera™ Studies at 2025 ASCO Annual Meeting

May 22, 2025

From Natera, Inc.

Via Business Wire

Here's How Much $100 Invested In Natera 5 Years Ago Would Be Worth Today ↗

May 12, 2025

Via Benzinga

8 Analysts Have This To Say About Natera ↗

May 09, 2025

Via Benzinga

Natera (NASDAQ:NTRA) Surprises With Strong Q1, Guides for Strong Full-Year Sales

May 08, 2025

Genetic testing company Natera (NASDAQ:NTRA). announced better-than-expected revenue in Q1 CY2025, with sales up 36.5% year on year to $501.8 million. The company’s full-year revenue guidance of $1.98...

Via StockStory

Natera Reports First Quarter 2025 Financial Results

May 08, 2025

From Natera, Inc.

Via Business Wire

Signatera Data From I-SPY 2 Trial to Be Presented at ESMO Breast Annual Congress

May 08, 2025

From Natera, Inc.

Via Business Wire

Prospera™ Heart Test with DQS Outperforms dd-cfDNA Percentage in Detecting Allograft Rejection, New AJT Publication Shows

May 07, 2025

From Natera, Inc.

Via Business Wire

What To Expect From Natera’s (NTRA) Q1 Earnings

May 07, 2025

Genetic testing company Natera (NASDAQ:NTRA). will be reporting earnings tomorrow after market hours. Here’s what you need to know.

Via StockStory

Topics Artificial Intelligence

Largest Sarcoma Study to Date with ctDNA Analysis Demonstrates Excellent Performance for Signatera

May 05, 2025

From Natera, Inc.

Via Business Wire

Natera to Report its First Quarter Results on May 8, 2025

May 01, 2025

From Natera, Inc.

Via Business Wire

Prospective DEFINE-HT Study Demonstrates that Prospera™ Heart is Predictive of Clinical Outcomes and Outperforms Biopsy in Predicting Graft Dysfunction

April 29, 2025

From Natera, Inc.

Via Business Wire

2 Healthcare Stocks on Our Watchlist and 1 to Be Wary Of

April 29, 2025

Healthcare companies are pushing the status quo by innovating in areas like drug development and digital health. Despite the rosy long-term prospects, short-term headwinds such as COVID inventory...

Via StockStory

Topics Stocks

If You Invested $100 In This Stock 5 Years Ago, You Would Have This Much Today ↗

April 28, 2025

Via Benzinga

Natera Announces Broad Clinical Launch of Ultra-Sensitive Signatera™ Genome MRD Test

April 24, 2025

From Natera, Inc.

Via Business Wire

Natera To Present Data from 8 Studies at 2025 AACR Annual Meeting

April 22, 2025

From Natera, Inc.

Via Business Wire

1 of Wall Street’s Favorite Stock for Long-Term Investors and 2 to Turn Down

April 18, 2025

Wall Street is overwhelmingly bullish on the stocks in this article, with price targets suggesting significant upside potential. However, it’s worth remembering that analysts rarely issue sell ratings,...

Via StockStory

< Previous 1 2

...

5 6 7 8 9 10 11 12 13

...

23 24 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.